Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Peanut Allergy Disease Clinical Trials Review - H1, 2021 - ResearchAndMarkets.com

July 14, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Jul 14, 2021--

The “Peanut Allergy Disease - Global Clinical Trials Review, H1, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of Peanut Allergy Clinical trials scenario. This report provides top line data relating to the clinical trials on Peanut Allergy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.


It Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The publisher Clinical Trial Reports are generated using the publisher’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Companies Mentioned

  • Aimmune Therapeutics Inc
  • DBV Technologies SA
  • F. Hoffmann-La Roche Ltd
  • Food Allergy Research & Education Inc
  • Sanofi
  • AnaptysBio Inc
  • Murdoch Childrens Research Institute
  • Novartis AG
  • Aravax Pty Ltd
  • Astellas Pharma Inc


  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to Buy


  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

1. Report Guidance

  • Clinical Trials Report Coverage

2. Clinical Trials by Region

  • Clinical Trials and Average Enrollment by Country
  • Top Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Clinical Trials by G7 Countries: Proportion of Peanut Allergy to Immunology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status

3. Clinical Trials by Phase

  • In Progress Trials by Phase

4. Clinical Trials by Trial Status

5. Clinical Trials by End Point Status

  • Subjects Recruited Over a Period of Time

6. Clinical Trials by Sponsor Type

  • Prominent Sponsors
  • Top Companies Participating in Peanut Allergy Therapeutics Clinical Trials

7. Prominent Drugs

  • Clinical Trial Profile Snapshots

8. Appendix

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/91qjnp

View source version on businesswire.com:https://www.businesswire.com/news/home/20210714005740/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 07/14/2021 11:58 AM/DISC: 07/14/2021 11:58 AM